IFNA1 and myeloproliferative disorder: Data from the DALIAH trial,22 a phase three randomized controlled trial of IFN‐α (including IFNα‐2a and IFNα‐2b) versus hydroxyurea (HU) in MPN patients, brought to light the most important information in this regards up to date.